Table 1.

GI50 values of TAI-95 in various breast cancer lines

MDA-MB-231MDA-MB-468T47DHs578TZR-75-1MCF7HCC1954BT474ZR-75-30MDA-MB-453MDA-MB-361
Paclitaxel3.00 nmol/L2.38 nmol/L3.19 nmol/L7.99 nmol/L>10 μmol/L>10 μmol/L>10 μmol/L5.40 nmol/L>10 μmol/L1.71 nmol/L>10 μmol/L
Doxorubicin213.80 nmol/L28.27 nmol/L7.22 nmol/L423.34 nmol/L134.87 nmol/L>10 μmol/L509.20 nmol/L158.56 nmol/L>10 μmol/L114.26 nmol/L>10 μmol/L
Topotecan346.73 nmol/L10.71 nmol/L9.43 nmol/L4513 nmol/L48.39 nmol/L>10 μmol/L675.90 nmol/L>10 μmol/L2334 nmol/L91.39 nmol/L303.92 nmol/L
Gemcitabine6.44 nmol/L5.04 nmol/L10.35 nmol/L>10 μmol/L5.23 nmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/LND>50 μmol/L
Irinotecan>10 μmol/L1997 nmol/L724.70 nmol/L>50 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>50 μmol/L>10 μmol/LND>50 μmol/L
Gefinitib>10 μmol/L9093 nmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L774.00 nmol/L4820 nmol/LND>10 μmol/L
Cisplatin>10 μmol/L>10 μmol/L>50 μmol/L>10 μmol/L>50 μmol/L>50 μmol/L>10 μmol/L>50 μmol/L>50 μmol/LND>50 μmol/L
Cyclophosphamide>500 μmol/L>500 μmol/L>500 μmol/L>50 μmol/L>50 μmol/L>50 μmol/L>50 μmol/L>50 μmol/L>50 μmol/LND>50 μmol/L
KX0143.41 nmol/L26.50 nmol/L51.98 nmol/L37.79 nmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L53.47 nmol/L32.18 nmol/L
Sorafenib3760 nmol/L3172 nmol/L1730 nmol/L7252 nmol/L4541 nmol/L>10 μmol/L4661 nmol/L4638 nmol/L4074 nmol/L3461 nmol/L4441 nmol/L
Sunitinib>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/LND>10 μmol/L
TAI-9516.48 nmol/L22.21 nmol/L14.29 nmol/L43.39 nmol/L52.35 nmol/L39.17 nmol/L25.46 nmol/L73.65 nmol/L25.47 nmol/L> 10 μmol/L> 10 μmol/L

Abbreviation: ND, not determined.